Emerging Therapies in Pretreated NMIBC

A roundtable discussion, moderated by Christopher Wallis, MD, PhD, FRCSC, focused on patient selection and treatment considerations for non-muscle invasive bladder cancer, including recent data from SUO 2023. Dr. Wallis was joined by Sia Daneshmand, MD; Piyush Agarwal, MD; and Sima Porten, MD, MPH.
In the next segment of the roundtable series, the panel considers emerging therapies across different risk stratifications, including implications from the ATLAS, ENVISION, and BOND-003 studies.